scholarly journals Role of Front-of-Package Gluten-Free Product Labeling in a Pair-Matched Study in Women with and without Celiac Disease on a Gluten-Free Diet

Nutrients ◽  
2019 ◽  
Vol 11 (2) ◽  
pp. 398 ◽  
Author(s):  
Wioleta Zysk ◽  
Dominika Głąbska ◽  
Dominika Guzek
Keyword(s):  
Celiac Disease ◽  
Free Product ◽  
Economic Status ◽  
Organic Production ◽  
Gluten Free ◽  
Place Of Residence ◽  
Product Labeling ◽  
Written Information ◽  
Selection Of

Gluten-free (GF) product labeling is one of the most important determinants of food product choices by patients with celiac disease, due to the need for following a GF diet. The aim of this study was to assess the role of front-of-package GF product labeling in pair-matched celiac and non-celiac women on a GF diet in a choice experiment (CE). In subgroups of celiac (n = 77) and non-celiac pair-matched respondents on a GF diet, but with no gluten-related diseases diagnosed (n = 77), the influence of front-of package labeling of GF bread on the choice of products was assessed. The labeling assessed in a CE included for all the products crossed grain logotype and additional logotypes of European Union (EU) organic production, “dairy-free” product, wheat starch-free product, quality and vegan product, as well as additional “gluten-free” written information. It was stated that the frequency of selection of products with “gluten-free” written information did not differ between subgroups of celiac and non-celiac respondents, as well as in subgroups stratified by age, body mass index (BMI), place of residence, and economic status. The frequency of selection of products with “vegan” logotype was higher for non-celiac respondents than for celiac ones (p = 0.0011). The frequency of selection of a product with additional logotypes was influenced by BMI and place of residence, but not by age and economic status of assessed women.

Role of pancreatic impairment in growth recovery during gluten-free diet in childhood celiac disease

1997 ◽  
Vol 112 (6) ◽  
pp. 1839-1844 ◽  
Author(s):  
A Carroccio ◽  
G Iacono ◽  
P Lerro ◽  
F Cavataio ◽  
E Malorgio ◽  
...  
Keyword(s):  
Celiac Disease ◽  
Gluten Free Diet ◽  
Gluten Free ◽  
Growth Recovery

Compliance with the Gluten-Free Diet: The Role of Locus of Control in Celiac Disease

2011 ◽  
Vol 158 (3) ◽  
pp. 463-466.e5 ◽  
Author(s):  
Anna Bellini ◽  
Chiara Zanchi ◽  
Stefano Martelossi ◽  
Grazia Di Leo ◽  
Tarcisio Not ◽  
...  
Keyword(s):  
Celiac Disease ◽  
Locus Of Control ◽  
Gluten Free Diet ◽  
Gluten Free

scholarly journals Should the Glu Be Ten or Twenty? An Update on the Ongoing Debate on Gluten Safety Limits for Patients with Celiac Disease

2020 ◽  
Vol 2 (3) ◽  
pp. 202-211
Author(s):  
Inna Spector Cohen ◽  
Andrew Day ◽  
Ron Shaoul
Keyword(s):  
Celiac Disease ◽  
Free Product ◽  
Daily Intake ◽  
Gluten Free ◽  
Ongoing Debate ◽  
Strict Adherence ◽  
General Consensus ◽  
Adherence To Diet ◽  
Recommended Treatment ◽  
Upper Limit

The only currently accepted and recommended treatment for individuals diagnosed with celiac disease (CD) is a strict life-long gluten-free diet (GFD). While the use of the GFD is well-established, strict adherence to diet is not easy to accomplish. In addition, the administration of a GFD may be compromised by inadvertent exposure to small amounts of gluten. International guidelines define a gluten-free product as one containing less than 20 parts per million (ppm), (20 milligrams of gluten per 1 kg of food) gluten. A number of reports have assessed the safe upper limit for gluten exposure for patients with CD, with general consensus that patients with CD should limit their daily intake to less than 50 mg.

Gynecological and Obstetric Findings in Brazilian Patients with Celiac Disease: The Role of a Gluten-free Diet

2015 ◽  
Vol 110 ◽  
pp. S995-S996
Author(s):  
Lorete Kotze ◽  
Renato Nisihara ◽  
Luiz Roberto Kotze ◽  
Shirley Utiyama
Keyword(s):  
Celiac Disease ◽  
Gluten Free Diet ◽  
Gluten Free

Intakes of nutrients in Italian children with celiac disease and the role of commercially available gluten-free products

2012 ◽  
Vol 26 (5) ◽  
pp. 436-444 ◽  
Author(s):  
G. Zuccotti ◽  
V. Fabiano ◽  
D. Dilillo ◽  
M. Picca ◽  
C. Cravidi ◽  
...  
Keyword(s):  
Celiac Disease ◽  
Gluten Free ◽  
Free Products ◽  
Italian Children

Role of the gluten-free diet on neurological EEG findings and sleep disordered breathing in children with celiac disease

2016 ◽  
Vol 48 ◽  
pp. e246
Author(s):  
C.M. Trovato ◽  
P. Parisi ◽  
M. Montuori ◽  
C. Anania ◽  
B. Buozzo ◽  
...  
Keyword(s):  
Celiac Disease ◽  
Sleep Disordered Breathing ◽  
Gluten Free Diet ◽  
Gluten Free ◽  
Disordered Breathing

Barriers to Compliance to Gluten-free Diet in Celiac Disease: The Role of Depression and Motivation

2013 ◽  
Vol 108 ◽  
pp. S468 ◽  
Author(s):  
Guy Weiss ◽  
Jeffrey Lackner ◽  
Craig Keller ◽  
Greg Gudleski ◽  
Cliff Hauck ◽  
...  
Keyword(s):  
Celiac Disease ◽  
Gluten Free Diet ◽  
Gluten Free

scholarly journals PNPLA3 rs738409 Polymorphism Predicts Development and Severity of Hepatic Steatosis but Not Metabolic Syndrome in Celiac Disease

Nutrients ◽  
2018 ◽  
Vol 10 (9) ◽  
pp. 1239 ◽  
Author(s):  
Raffaella Tortora ◽  
Antonio Rispo ◽  
Anna Alisi ◽  
Nicola Imperatore ◽  
Annalisa Crudele ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Celiac Disease ◽  
Hepatic Steatosis ◽  
Odds Ratio ◽  
Binary Logistic Regression ◽  
Control Group ◽  
Gluten Free ◽  
Key Factor ◽  
Severe Grade

Metabolic syndrome (MS) and hepatic steatosis (HS) have been described in patients with celiac disease (CD) after starting a gluten-free diet (GFD), but data on predictive factors for these conditions are scarce. Recently, the patatin-like phospholipase domain-containing protein 3 (PNPLA3) rs738409 has been identified as a key factor for HS development in the general population. The aim of the study was to evaluate the role of PNPLA3 rs738409 in the development of MS and HS in CD patients after starting GFD. Between June 2014 and September 2016, we consecutively enrolled CD patients with HS, while those without steatosis served as a control group. All patients underwent anthropometric and serologic investigations, ultrasonography (US) to assess the degree and severity of HS, and genotyping of the PNPLA3 rs738409 polymorphism. Finally, 370 subjects were enrolled (136 with and 234 without HS). At genotyping assays, the CC genotype was found in 194 subjects (52.4%), the CG genotype in 138 subjects (37.3%), and the GG genotype in 38 subjects (10.2%). At binary logistic regression, only CG and GG alleles were predictive for the development of HS (odds ratio (OR) 1.97; p < 0.01 for CG and OR 6.9; p < 0.001 for GG). Body mass index (BMI) (OR 3.8; p < 0.001) and waist circumference (OR 2.8; p = 0.03) at CD diagnosis were the only independent factors for the development of MS. Intergroup comparisons showed that the severe grade of HS was more frequently observed in GG than in CC carriers (74% vs. 11.3%, p < 0.001, OR 21.8). PNPLA3 CG and GG carriers with CD have a higher susceptibility to hepatic steatosis, but not to metabolic syndrome. Moreover, patients with GG alleles display more severe forms of HS based on ultrasound.

M2033 Role of Antibodies in the Long Term Follow Up of Patients with Celiac Disease to Predict the Adherence to Gluten-Free Diet

2009 ◽  
Vol 136 (5) ◽  
pp. A-471
Author(s):  
Adriana Mohaidle ◽  
José M. Mella ◽  
Lisandro Pereyra ◽  
Pablo Luna ◽  
Carolina Fischer ◽  
...  
Keyword(s):  
Celiac Disease ◽  
Gluten Free Diet ◽  
Gluten Free ◽  
Long Term Follow Up
Sign in / Sign up

Export Citation Format

Share Document